Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
Status:
Terminated
Trial end date:
2019-01-15
Target enrollment:
Participant gender:
Summary
Radioiodine refractory differentiated thyroid cancer is a rare tumor and therapeutic options
are limited in this setting. Molecular targeted therapies have recently been developed for
progressive disease and demonstrated clinical activity, especially with anti-angiogenic
agents.
For patients with contra-indication to these agents or in case of progression or toxicity
during treatment, chemotherapy is usually proposed but this strategy has not been validated
by prospective data.
The investigators propose to conduct an open single arm phase 2 study to evaluate response
rate according to RECIST 1.1 with GEMOX regimen (gemcitabine - oxaliplatin combination) for
advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic
agents or in case of contra-indication to anti-angiogenic therapy.